Vertex Current Deferred Revenue from 2010 to 2026

VRTX Stock  USD 465.02  3.78  0.82%   
Vertex Pharmaceuticals Current Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Current Deferred Revenue is likely to outpace its year average in 2026. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2000-12-31
Previous Quarter
220 M
Current Value
206.8 M
Quarterly Volatility
108.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 13.3 B, Gross Profit of 11.5 B or Other Operating Expenses of 13.6 B, as well as many indicators such as Price To Sales Ratio of 10.28, Dividend Yield of 0.0 or PTB Ratio of 7.62. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Vertex Stock
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
The evolution of Current Deferred Revenue for Vertex Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vertex Pharmaceuticals compares to historical norms and industry peers.

Latest Vertex Pharmaceuticals' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Vertex Pharmaceuticals over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Vertex Pharmaceuticals' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Vertex Current Deferred Revenue Regression Statistics

Arithmetic Mean152,655,529
Geometric Mean96,625,365
Coefficient Of Variation88.04
Mean Deviation95,960,789
Median163,132,000
Standard Deviation134,396,666
Sample Variance18062.5T
Range537.8M
R-Value0.48
Mean Square Error14853.6T
R-Squared0.23
Significance0.05
Slope12,737,466
Total Sum of Squares288999.4T

Vertex Current Deferred Revenue History

2026249.7 M
2025237.8 M
2024206.8 M
2023170.3 M
2022159.6 M
2021171.7 M
2020191.5 M

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue237.8 M249.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.